Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation

Stroke

Volumn 29, Issue 6, 1998, Pages 1083-1091

  Gage, Brian F ^a,b   Cardinalli, Andria B ^c   Owens, Douglas K ^c  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Aspirin; Atrial fibrillation costs and cost analysis; Stroke prevention; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK FACTOR; STROKE; SURVIVAL;

EID: 0031801219     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.6.1083     Document Type: Article

References (92)

1. The European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stoke. Lancet. 1993;342:1255-1262.
2. Connolly SJ. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355.
3. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D, for the VA Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
4. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation (SPAF) Study: final results. Circulation. 1991;84:527-539.
5. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
6. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet. 1989;1:175-179.
7. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
8. Laupacis A, Boysen G, Connolly S, Ezekowitz M, Hart B, James K, Kistler P, Kronmal R, Petersen P, Singer D. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154: 1449-1457.
9. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med. 1995;332:238-248.
10. Laupacis A, Boysen G, Connolly S, Ezekowitz M, Hart B, James K, Singer D, Koudstaal P, Kistler P, Kronmal R, McBride R, Petersen P. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1997;157: 1237-1240.
11. Antiplatelet Trialists' Collaborators. Collaborative overview of randomised trials of antiplatelet therapy, 1. BMJ. 1994;308:81-106.
12. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
13. Laupacis A, Albers GW, Dalen JE, Dunn MI, Feinberg W, Jacobson AK. Antithrombotic therapy in atrial fibrillation. Chest. 1995;108(suppl): 352-359.
14. Matchar DB, McCrory DC, Barnett HJM, Feussner JR. Medical treatment for stroke prevention. Ann Intern Med. 1994;121:41-53.
15. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
16. Nease RF, Owens DK. A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making. 1994;14:382-392.
17. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Economic Planning Sci. 1976;10:129-136.
18. Owens DK, Sox HC. Medical decision making: probabilistic medical reasoning. In: Shortliffe EH, Perreault LE, Pagan LM, Wiederhold G, eds. Medical Informatics: Computer Applications in Medicine. Reading, Mass: Addison-Wesley; 1990:70-116.
19. Sumner W, Nease R, Littenberg B. U-titer: a utility assessment tool. In: Proceedings of the Fifteenth Annual Symposium on Computer Applications in Medical Care; November 17-20, 1991; Washington, DC. 701-705.
20. Eckman MH, Levine HJ, Pauker SG. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest. 1995;108(suppl):457-470.
21. Naglie G, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making. 1992;12:239-249.
22. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992;305:1457-1460.
23. Cabin HS, Clubb KS, Hall C, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol. 1990;65:1112-1116.
24. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-1022.
25. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med. 1992;116:1-5.
26. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5-10.
27. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546.
28. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
29. Nadeau SE. The use of expected value as an aid to decisions regarding anticoagulation in patients with atrial fibrillation. Stroke. 1993;24: 2128-2134.
30. Man-Son-Hing M, Laupacis A, O'Connor A, Wells G, Lemelin J, Wood W, Dermer M. Warfarin for atrial fibrillation: the patient's perspective. Arch Intern Med. 1996;156:1841-1848.
31. Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage BF. Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J. In press.
32. Matchar D, Samsa G, Bonito A, Witter D. Use of anticoagulation to prevent strokes: results from an outpatient chart audit. J Gen Intern Med. 1996;11(suppl):126. Abstract.
33. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
34. Albers GW, Yim JM, Belew KM, Bittar N, Hattemer CR, Phillips BG, Kemp S, Hall EA, Morton DJ, Vlasses PH. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med. 1996;156:2311-2316.
35. Antani MR, Beyth RJ, Covinsky KE, Anderson PA, Miller DG, Cebul RD, Quinn LM, Landefeld CS. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med. 1996;11:713-720.
36. Beyth RJ, Antani MR, Covinsky KE, Miller DG, Chren M-M, Quinn LM, Landefeld CS. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med. 1996;11:721-728.
37. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med. 1997;157:441-445.
38. Gurwitz JH, Monette J, Rochon P, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med. 1997;157:978-984.
39. Lip GYH, Zarifis J, Watson RDS, Beevers DG. Physician variation in the management of patients with atrial fibrillation. Heart. 1996;75:200-205.
40. Matchar DB, McCrory DC, Barnett HJM, Feussner JR. Guidelines for medical treatment for stroke prevention. Ann Intern Med. 1994;121:54-55.
41. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995;155:469-473.
42. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902.
43. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med. 1993;153:1557-1562.
44. Solomon NA, Click HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke. 1994;25:1721-1725.
45. Patrick DL, Starks HE, Cain KC, Uhlmann RF, Pearlman RA. Measuring preferences for health states worse than death. Med Decis Making. 1994; 14:9-18.
46. O'Meara JJ, McNutt RA, Evans AT, Moore SW, Downs SM. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med. 1994;330:1864-1869.
47. Regel KM, Hutchinson TA, Groome PA, Tousignant P. Factors relevant to preventing embolic stroke in patients with non-rheumatic atrial fibrillation. J Clin Epidemiol. 1991;44:551-560.
48. Lancaster TR, Singer DE, Sheehan MA, Oertel LB, Maraventano SW, Hughes RA, Kistler JP. The impact of long-term warfarin therapy on quality of life: evidence from a randomized trial. Arch Intern Med. 1991;151:1944-1949.
49. Wolfson AD, Sinclair A, Bombardier C, McGeer A. Preference measurements for functional status in stroke patients: interrater and inter-technique comparisons. In: Kane RL, Kane RA, eds. Values in Long Term Care. Ontario, Canada: DC Heath; 1982:191-214.
50. Beck JR, Pauker SG. Anticoagulation and atrial fibrillation in the bradycardia-tachycardia syndrome. Med Decis Making. 1981;1: 284-301.
51. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest. 1992;102(suppl 4):426S-433S.
52. Klein MD. Atrial fibrillation: new findings about an old nemesis. Hosp Pract (Off Ed). 1991;26:75-78, 81-82, 85-88.
53. Prystowsky EN, Benson Jr W, Fuster V, Hart RG, Kay N, Myerburg RJ, Naccarelli GV, Wyse G. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996;93:1262-1277.
54. Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med. 1996;125:311-323.
55. Littenberg B, Garber AM, Sox HC. Screening for hypertension. Ann Intern Med. 1990;112:192-202.
56. Greenfield S, Kaplan SH, Ware JE Jr, Yano EM, Frank HJL. Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes. J Gen Intern Med. 1988;3:448-457.
57. Rost KM, Flavin KS, Cole K, McGill JB. Change in metabolic control and functional status after hospitalization: impact of patient activation intervention in diabetic patients. Diabetes Care. 1991;14:881-889.
58. Kaplan SH, Greenfield S, Ware JE Jr. Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care. 1989; 27(suppl 3):S110-S127.
59. Kaplan SH, Greenfield S, Dukes K. Effects of a joint physician-patient intervention program on health outcomes and interpersonal care. J Gen Intern Med. 1993;41:541A. Abstract.
60. Szabo E, Moody H, Hamilton T, Ang C, Kovithavongs C, Kjellstrand C. Choice of treatment improves quality of life: a study of patients undergoing dialysis. Arch Intern Med. 1997;157:1352-1356.
61. Fallowfield LJ, Hall A, Maguire GP, Baum M. Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. BMJ. 1990;301:575-580.
62. Kaplan SH, Greenfield S, Gandek B, Rogers WH, Ware JE Jr. Characteristics of physicians with participatory decision-making styles. Ann Intern Med. 1996;124:497-504.
63. Thompson CE, Wankel LM. The effects of perceived activity choice upon frequency of exercise behaviour. J Appl Soc Psychol. 1980;10:436-443.
64. Janis I, Mann L. Decision Making: A Psychological Analysis of Conflict, Choice, and Commitment. New York, NY: Free Press; 1977.
65. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236-241.
66. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA. 1985;254:3449-3453.
67. Hunt D, Holbrook A, Rawnsley K, Cook D, Millar S. Atrial fibrillation: predictors of warfarin prescription. J Gen Intern Med. 1996:11(suppl):47. Abstract.
68. Lip GYH, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J. 1994;71:92-95.
69. Lackner TE, Battis GN. Use of warfarin for nonvalvular atrial fibrillation in nursing home patients. Arch Family Med. 1995;4:1017-1026.
70. Caro JJ, Groome PA, Flegel KM. Atrial fibrillation and anticoagulation: from randomised trials to practice. Lancet. 1993;341:1381-1384.
71. Flegel KMm Shipley MJm Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet. 1987;1:526-529.
72. Christensen-Szalanski JJ. Discount functions and the measurement of patients' values: women's decisions during childbirth. Med Decis Making. 1984;4:47-58.
73. Llewellyn-Thomas HA, Sutherland HJ, Thiel EC. Do patients' evaluations of a future health state change when they actually enter that state? Med Care. 1993;11:1002-1012.
74. Kasper JF, Fowler FJ Jr. Responding to the challenge: a status report on shared decision-making programs. HMO Practice. 1993;7:176-181.
75. McNeil BJ, Weichselbaum R, Pauker SG. Speech and survival: Tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med. 1981;305:982-987.
76. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med. 1994;330:1895-1896.
77. Weinstein M, Stason W. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721.
78. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med. 1994;154:1443-1448.
79. Stroke Prevention in Atrial Fibrillation Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990;322:863-868.
80. Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke: the Framingham Study. Stroke. 1982;13:290-295.
81. Dennis MS, Burn JPS, Sandercock PAG, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796-800.
82. Candelise L, Pinardi G, Morabito A, for the Italian Acute Stroke Study Group. Mortality in acute stroke with atrial fibrillation. Stroke. 1991;22: 169-174.
83. Landefeld SC, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med. 1993;95:315-328.
84. US Bureau of the Census. Statistical Abstract of the United States. Washington, DC: US Government Printing Office; 1992.
85. Yuan Z, Bowlin S, Einstadter D, Cebul R, Conners A, Rimm A. Atrial fibrillation as a risk factor for stroke: a retrospective cohort study of hospitalized Medicare beneficiaries. Am J Public Health. 1998;88: 395-400.
86. Eckman MH, Levine HJ, Pauker SG. Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. Chest. 1992;102(suppl 4):538S-549S.
87. Smurawaska LT, Alexandrov AV, Bladin CF, Norris JW. Cost of acute stroke care in Toronto, Canada. Stroke. 1994;25:1628-1631.
88. Hartunian N, Smart C, Thompson M. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. Am J Public Health. 1980;70:1249-1260.
89. Carter GM, Melnick GA. How Services and Costs Vary by Day of Stay for Medicare Hospital Stays. Santa Monica, Calif: Rand Corp; 1990.
90. Thorngren M, Westling B. Utilization of health care resources after stroke: a population-based study of 258 hospitalized cases followed during the first year. Acta Neurol Scand. 1991;84:303-310.
91. Health Care Investment Analysts Inc. The Medicare DRG Handbook: Comparative Clinical and Financial Standards. Baltimore, Md: Ernst & Young; 1991.
92. The Swedish Council on Technology Assessment in Health Care (SBU). Stroke [in Swedish]. Stockholm, Sweden: SBU; 1993.